Original Article

You have full text access to this OnlineOpen article

Correlation between clinical outcome and growth factor pathway expression in osteogenic sarcoma†‡

  1. Ayesha Abdeen MD1,
  2. Alexander J. Chou MD2,
  3. John H. Healey MD1,
  4. Chand Khanna DVM, PhD3,
  5. Tanasa S. Osborne DVM3,
  6. Stephen M. Hewitt MD, PhD4,
  7. Mimi Kim ScD5,
  8. Dan Wang MS5,
  9. Karen Moody MD6,
  10. Richard Gorlick MD6,§,*

Article first published online: 10 AUG 2009

DOI: 10.1002/cncr.24562

Issue

Cancer

Cancer

Volume 115, Issue 22, pages 5243–5250, 15 November 2009

Additional Information

How to Cite

Abdeen, A., Chou, A. J., Healey, J. H., Khanna, C., Osborne, T. S., Hewitt, S. M., Kim, M., Wang, D., Moody, K. and Gorlick, R. (2009), Correlation between clinical outcome and growth factor pathway expression in osteogenic sarcoma. Cancer, 115: 5243–5250. doi: 10.1002/cncr.24562

Author Information

  1. 1

    Department of Orthopaedic Surgery, Memorial Sloan-Kettering Cancer Center, Weill Medical College of Cornell University, New York, New York

  2. 2

    Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, Weill Medical College of Cornell University, New York, New York

  3. 3

    Tumor and Metastasis Biology Section, Pediatric Oncology Branch, LLR, National Cancer Institute, Bethesda, Maryland

  4. 4

    TARP, Laboratory of Pathology, LLR, National Cancer Institute, Bethesda, Maryland

  5. 5

    Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, New York

  6. 6

    Department of Pediatrics, Montefiore Medical Center, Albert Einstein College of Medicine, Yeshiva University, Bronx, New York

  1. §

    Fax: (718) 920-6506

*Division of Pediatric Hematology-Oncology, The Children's Hospital at Montefiore, 3415 Bainbridge Avenue, Rosenthal Building, Room 300, Bronx, NY 10467

  1. †

    This article is US Government work and, as such, is in the public domain in the United States of America.

  2. ‡

    Presented as a poster at the Annual Meeting of the American Association of Cancer Research, San Diego, California, April 12-16, 2008.

Publication History

  1. Issue published online: 3 NOV 2009
  2. Article first published online: 10 AUG 2009
  3. Manuscript Accepted: 26 MAR 2009
  4. Manuscript Revised: 9 MAR 2009
  5. Manuscript Received: 11 NOV 2008

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (217K)

References

  • 1
    Bacci G, Longhi A, Versari M, et al. Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution. Cancer. 2006; 106: 1154-1161.
    Direct Link:
  • 2
    Meyers PA, Schwartz CL, Krailo MD, et al. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival—a report from the Children's Oncology Group. J Clin Oncol. 2008; 26: 633-638.
  • 3
    Meyers PA, Heller G, Healey JH, et al. Osteogenic sarcoma with clinically detectable metastasis at initial presentation. J Clin Oncol. 1993; 11: 449-453.
  • 4
    Enneking WF, Spanier SS, Goodman MA. A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop Relat Res. 1980; 415: 106-120.
  • 5
    Khanna C, Prehn J, Hayden D, et al. A randomized controlled trial of octreotide pamoate long-acting release and carboplatin versus carboplatin alone in dogs with naturally occurring osteosarcoma: evaluation of insulin-like growth factor suppression and chemotherapy. Clin Cancer Res. 2002; 8: 2406-2412.
  • 6
    Huvos AG, Rosen G, Marcove RC. Primary osteogenic sarcoma: pathologic aspects in 20 patients after treatment with chemotherapy en bloc resection, and prosthetic bone replacement. Arch Pathol Lab Med. 1977; 101: 14-18.
  • 7
    Meyers PA, Heller G, Healey J, et al. Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience. J Clin Oncol. 1992; 10: 5-15.
  • 8
    Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B. 1995; 57: 289-300.
  • 9
    Kaya M, Wada T, Akatsuka T, et al. Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis. Clin Cancer Res. 2000; 6: 572-577.
  • 10
    Hoang BH, Dyke JP, Koutcher JA, et al. VEGF expression in osteosarcoma correlates with vascular permeability by dynamic MRI. Clin Orthop Relat Res. 2004; 426: 32-38.
  • 11
    Lee YH, Tokunaga T, Oshika Y, et al. Cell-retained isoforms of vascular endothelial growth factor (VEGF) are correlated with poor prognosis in osteosarcoma. Eur J Cancer. 1999; 35: 1089-1093.
View Full Article (HTML) Get PDF (217K)